Treatment outcomes of 200 adult non-L3 ALL patients, by karyotype and ploidy categories
| Category . | No. of patients . | Complete remission . | Resistant disease . | Overall survival at 5 y* . | Relapse-free survival at 5 y† . | Disease-free survival at 5 y‡ . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % . | 95% CI, % . | % . | 95% CI, % . | Est. % . | 95% CI, % . | Est. % . | 95% CI, % . | Est. % . | 95% CI, % . | ||
| Normal diploid | 31 | 87 | 70-96 | 10 | 2-26 | 50 | 32-68 | 43 | 24-62 | 64 | 39-89 |
| t(9;22)/BCR/ABL1 | 36 | 67 | 49-81 | 19 | 8-36 | 8 | 2-22 | 0 | 0-14 | 0 | 0-34 |
| Other unfavorable§ | 19 | 79 | 54-94 | 16 | 3-40 | 26 | 9-51 | 33 | 9-57 | 50 | 15-85 |
| Miscellaneous | 54 | 81 | 69-91 | 4 | 0-13 | 52 | 38-65 | 41 | 26-56 | 45 | 23-66 |
| P‖¶ | .21 | .091 | <.001 | <.001 | .006 | ||||||
| Not evaluable | 60 | 82 | 70-90 | 10 | 4-21 | 26 | 15-37 | 24 | 12-36 | 30 | 13-48 |
| Normal diploid | 31 | 87 | 70-96 | 10 | 2-26 | 50 | 32-68 | 43 | 24-62 | 64 | 39-89 |
| Hypodiploid | 11 | 73 | 39-94 | 27 | 6-61 | 24 | 0-51 | 38 | 4-71 | —** | — |
| Pseudodiploid | 45 | 78 | 63-89 | 4 | 1-15 | 42 | 27-56 | 39 | 23-55 | 58 | 34-82 |
| Hyperdiploid | 38 | 71 | 54-85 | 13 | 4-28 | 33 | 17-48 | 26 | 9-42 | 24 | 3-44 |
| P‖# | .42 | .18 | .38 | .82 | .10 | ||||||
| Other | 6 | 83 | 36-100 | 17 | 0-64 | 17 | 0-64 | 0 | 0-52 | —** | — |
| Not evaluable | 69 | 83 | 72-91 | 10 | 4-20 | 24 | 14-34 | 20 | 10-31 | 26 | 11-42 |
| Category . | No. of patients . | Complete remission . | Resistant disease . | Overall survival at 5 y* . | Relapse-free survival at 5 y† . | Disease-free survival at 5 y‡ . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| % . | 95% CI, % . | % . | 95% CI, % . | Est. % . | 95% CI, % . | Est. % . | 95% CI, % . | Est. % . | 95% CI, % . | ||
| Normal diploid | 31 | 87 | 70-96 | 10 | 2-26 | 50 | 32-68 | 43 | 24-62 | 64 | 39-89 |
| t(9;22)/BCR/ABL1 | 36 | 67 | 49-81 | 19 | 8-36 | 8 | 2-22 | 0 | 0-14 | 0 | 0-34 |
| Other unfavorable§ | 19 | 79 | 54-94 | 16 | 3-40 | 26 | 9-51 | 33 | 9-57 | 50 | 15-85 |
| Miscellaneous | 54 | 81 | 69-91 | 4 | 0-13 | 52 | 38-65 | 41 | 26-56 | 45 | 23-66 |
| P‖¶ | .21 | .091 | <.001 | <.001 | .006 | ||||||
| Not evaluable | 60 | 82 | 70-90 | 10 | 4-21 | 26 | 15-37 | 24 | 12-36 | 30 | 13-48 |
| Normal diploid | 31 | 87 | 70-96 | 10 | 2-26 | 50 | 32-68 | 43 | 24-62 | 64 | 39-89 |
| Hypodiploid | 11 | 73 | 39-94 | 27 | 6-61 | 24 | 0-51 | 38 | 4-71 | —** | — |
| Pseudodiploid | 45 | 78 | 63-89 | 4 | 1-15 | 42 | 27-56 | 39 | 23-55 | 58 | 34-82 |
| Hyperdiploid | 38 | 71 | 54-85 | 13 | 4-28 | 33 | 17-48 | 26 | 9-42 | 24 | 3-44 |
| P‖# | .42 | .18 | .38 | .82 | .10 | ||||||
| Other | 6 | 83 | 36-100 | 17 | 0-64 | 17 | 0-64 | 0 | 0-52 | —** | — |
| Not evaluable | 69 | 83 | 72-91 | 10 | 4-20 | 24 | 14-34 | 20 | 10-31 | 26 | 11-42 |
Est. indicates estimated.
Five years after study entry.
Five years after complete remission.
Five years after start of maintenance chemotherapy (maintenance patients only).
Other unfavorable is defined by the presence of −7, +8, and 11q23/MLL gene rearrangements.
P values based on logistic (complete remission, resistant disease) or proportional hazards (overall survival, relapse-free survival, disease-free survival) regression analysis.
P value for heterogeneity of outcomes among four categories with evaluable karyotype.
P value for heterogeneity of outcomes among four ploidy categories (normal, hypodiploid, pseudodiploid, and hyperdiploid).
DFS was not estimated for hypodiploid (N = 2) and other (N = 0) ploidy categories.